Literature DB >> 25960301

Metformin Use in Type 2 Diabetes Mellitus With CKD: Is It Time to Liberalize Dosing Recommendations?

Robert C Stanton1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25960301     DOI： 10.1053/j.ajkd.2015.04.001

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  5 in total

1.  Therapy: Risk of metformin use in patients with T2DM and advanced CKD.

Authors:  Guntram Schernthaner; Marie Helene Schernthaner-Reiter
Journal:  Nat Rev Endocrinol       Date:  2015-08-18       Impact factor: 43.330

2.  Further clarifying the relationship between metformin, acute kidney injury and lactic acidosis.

Authors:  Connie M Rhee; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2017-12-13       Impact factor: 28.314

3.  Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data.

Authors:  Connie M Rhee; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephron       Date:  2016-10-20       Impact factor: 2.847

4.  Restricting Metformin in CKD: Continued Caution Warranted.

Authors:  Connie M Rhee; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2015-12       Impact factor: 8.860

Review 5.  Metformin associated lactic acidosis (MALA): clinical profiling and management.

Authors:  Alessandra Moioli; Barbara Maresca; Andrea Manzione; Antonello Maria Napoletano; Daniela Coclite; Nicola Pirozzi; Giorgio Punzo; Paolo Menè
Journal:  J Nephrol       Date:  2016-01-22       Impact factor: 3.902
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.